Optimizing VLP production in gene therapy: Opportunities and challenges for in silico modeling

5Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Over the past decades, virus-like particle (VLP)-based gene therapy (GT) evolved as a promising approach to cure inherited diseases or cancer. Tremendous costs due to inefficient production processes remain one of the key challenges despite considerable efforts to improve titers. This review aims to link genome-scale metabolic models (GSMMs) to cell lines used for VLP synthesis for the first time. We summarize recent advances and challenges of GSMMs for Chinese hamster ovary (CHO) cells and provide an overview of potential cell lines used in GT. Although GSMMs in CHO cells led to significant improvements in growth rates and recombinant protein (RP)-production, no GSMM has been established for VLP production so far. To facilitate the generation of GSMM for these cell lines we further provide an overview of existing omics data and the highest production titers so far reported.

Cite

CITATION STYLE

APA

Zehetner, L., Széliová, D., Kraus, B., Graninger, M., Zanghellini, J., & Hernandez Bort, J. A. (2023, July 1). Optimizing VLP production in gene therapy: Opportunities and challenges for in silico modeling. Biotechnology Journal. John Wiley and Sons Inc. https://doi.org/10.1002/biot.202200636

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free